JP2021535173A5 - - Google Patents

Info

Publication number
JP2021535173A5
JP2021535173A5 JP2021511655A JP2021511655A JP2021535173A5 JP 2021535173 A5 JP2021535173 A5 JP 2021535173A5 JP 2021511655 A JP2021511655 A JP 2021511655A JP 2021511655 A JP2021511655 A JP 2021511655A JP 2021535173 A5 JP2021535173 A5 JP 2021535173A5
Authority
JP
Japan
Prior art keywords
composition according
tauroridine
composition
method described
administered
Prior art date
Application number
JP2021511655A
Other languages
English (en)
Japanese (ja)
Other versions
JP7530351B2 (ja
JP2021535173A (ja
JPWO2020047103A5 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/048579 external-priority patent/WO2020047103A1/en
Publication of JP2021535173A publication Critical patent/JP2021535173A/ja
Publication of JPWO2020047103A5 publication Critical patent/JPWO2020047103A5/ja
Publication of JP2021535173A5 publication Critical patent/JP2021535173A5/ja
Application granted granted Critical
Publication of JP7530351B2 publication Critical patent/JP7530351B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021511655A 2018-08-28 2019-08-28 若年哺乳動物の身体における神経芽細胞腫を治療するための方法および組成物 Active JP7530351B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862723592P 2018-08-28 2018-08-28
US62/723,592 2018-08-28
PCT/US2019/048579 WO2020047103A1 (en) 2018-08-28 2019-08-28 Methods and compositions for treating neuroblastoma in a juvenile mammalian body

Publications (4)

Publication Number Publication Date
JP2021535173A JP2021535173A (ja) 2021-12-16
JPWO2020047103A5 JPWO2020047103A5 (https=) 2022-09-02
JP2021535173A5 true JP2021535173A5 (https=) 2022-09-02
JP7530351B2 JP7530351B2 (ja) 2024-08-07

Family

ID=69645361

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021511655A Active JP7530351B2 (ja) 2018-08-28 2019-08-28 若年哺乳動物の身体における神経芽細胞腫を治療するための方法および組成物

Country Status (7)

Country Link
EP (1) EP3843745A4 (https=)
JP (1) JP7530351B2 (https=)
KR (1) KR102904381B1 (https=)
CN (1) CN113164491A (https=)
AU (1) AU2019330831B2 (https=)
CA (1) CA3111015A1 (https=)
WO (1) WO2020047103A1 (https=)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6479481B1 (en) 1999-06-04 2002-11-12 Ed. Geistlich Soehne Ag Fur Chemische Industrie Methods and compositions for treating primary and secondary tumors of the central nervous system (CNS)
US7345039B2 (en) * 1999-06-04 2008-03-18 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Enhancement of effectiveness of 5-fluorouracil in treatment of tumor metastases and cancer
JP5027369B2 (ja) 1999-12-06 2012-09-19 ガイストリッヒ ファーマ アーゲー 腫瘍を治療する方法
ATE354380T1 (de) * 2003-02-03 2007-03-15 Polaschegg Hans-Dietrich Dr Te Zusammensetzung zur prävention von infektionen durch subkutane prothesen
US20080177217A1 (en) * 2004-05-14 2008-07-24 Hans-Dietrich Polaschegg Taurolidine Formulations and Delivery: Therapeutic Treatments and Antimicrobial Protection Against Bacterial Biofilm Formation
WO2013190355A1 (en) * 2012-06-18 2013-12-27 Geistlich Pharma Ag Oxathiazine derivatives as antibacterial and anticancer agents
EP3402527B1 (en) 2016-01-11 2022-09-28 CorMedix Inc. Therapeutic nanoparticles for the treatment of neuroblastoma and other cancers
CN106974901A (zh) * 2016-01-18 2017-07-25 贵州益佰制药股份有限公司 洛铂在制备治疗神经母细胞瘤药物中的应用
WO2018129061A1 (en) * 2017-01-05 2018-07-12 Cormedix Inc. Antimicrobial delivery system for the prevention and treatment of infections in the colon

Similar Documents

Publication Publication Date Title
ES2198196B2 (es) Composiciones topicas que comprenden un analgesico opioide y un antagonista de nmda.
RU2015144666A (ru) Терапия для лечения рака, включающая антитела против клаудина 18.2
CN100411628C (zh) 空间位阻的铂配位化合物与非铂抗癌剂的组合及其应用
JP2015523355A5 (https=)
Zorzi et al. A phase I study of histone deacetylase inhibitor, pracinostat (SB939), in pediatric patients with refractory solid tumors: IND203 a trial of the NCIC IND program/C17 pediatric phase I consortium
CA2412795A1 (en) Improved liposomal camptothecins and uses thereof
NZ592039A (en) Combination therapy for the treatment of ocular neovascular disorders
DK1453487T3 (da) Farmaceutisk doseringsform med flere belægninger for reduceret virkning af belægningsbrud
Hande et al. Randomized study of high-dose versus low-dose methotrexate in the treatment of extensive small cell lung cancer
JP2005008534A (ja) 抗癌剤及び癌の治療方法
Hanada et al. Development and pharmacological verification of a new mouse model of central post-stroke pain
EE200200565A (et) Vaskulaarse kahjustava toimega kombinatsioonravi
JP2006513184A5 (https=)
AR078170A1 (es) Metodos para el tratamiento de tumores cerebrales
JP2021535163A5 (https=)
CN102438608A (zh) 包含ave8062和索拉非尼的抗肿瘤组合
RU2011101771A (ru) Педиатрические композиции для лечения рассеянного склероза
JP2013523678A5 (https=)
JP2021535173A5 (https=)
FI3359572T3 (fi) Menetelmä multippeliskleroosin hoitamiseksi
KR20210050544A (ko) 타우로리딘 가수분해 생성물을 이용한 신경모세포종 치료
JP2006528696A (ja) 抗癌剤の抗腫瘍活性を増強する方法
HRP20171708T1 (hr) FARMACEUTSKI PRIPRAVAK KOJI SADRŽI (1R,4R)-6'-FLUORO-N,N-DIMETIL-4-FENIL-4',9'-DIHIDRO-3'H-SPIRO[CIKLOHEKSAN-1,1'-PIRANO [3,4,b]INDOL]-4-AMIN I GABAPENTINOID
JPWO2020047103A5 (https=)
JPH10167969A (ja) 姑息的腫瘍療法でのドーパミンレセプター−アンタゴニストの使用